开能健康(300272) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was CNY 410,086,351.33, representing a year-on-year increase of 15.95% and a year-to-date increase of 31.44% to CNY 1,105,083,748.49[3] - The net profit attributable to shareholders for Q3 2021 was CNY 28,247,273.29, a decrease of 29.33% compared to the same period last year, while the year-to-date net profit increased by 20.84% to CNY 85,076,950.55[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was CNY 21,580,786.31, down 43.35% year-on-year, with a year-to-date figure of CNY 74,208,007.44, up 12.80%[3] - The company reported a basic earnings per share of CNY 0.05 for Q3 2021, down 28.57% year-on-year, while the diluted earnings per share remained the same[3] - Total operating revenue for Q3 2021 reached ¥1,105,083,748.49, an increase of 31.5% compared to ¥840,756,944.40 in Q3 2020[29] - Net profit for Q3 2021 was ¥99,969,154.95, representing a 13.9% increase from ¥87,857,281.99 in Q3 2020[30] - The net profit attributable to the parent company for Q3 2021 was ¥85,076,950.55, an increase from ¥70,404,264.73 in the same period last year, representing a growth of approximately 20.5%[31] - The total comprehensive income attributable to the parent company for Q3 2021 was ¥84,470,927.12, compared to ¥67,601,395.45 in Q3 2020, reflecting an increase of about 25%[31] Assets and Liabilities - The company's total assets as of September 30, 2021, were CNY 2,048,755,887.53, an increase of 12.67% compared to the end of the previous year[3] - Total assets amounted to CNY 1,818,405,772.85, a decrease of CNY 46,335,027.10 compared to the previous period[37] - Total liabilities increased to ¥804,796,654.23 from ¥601,901,272.25, a rise of 33.7%[27] - The company's total liabilities increased significantly, with long-term borrowings rising by 52.92% to CNY 8,380,000.00 from CNY 5,480,000.00, attributed to new loans taken by subsidiaries[8] - Total liabilities reached CNY 601,901,272.25, a decrease of CNY 46,335,027.10 from the previous period[38] - Current liabilities totaled CNY 489,929,439.25, showing a decrease of CNY 8,991,349.06[38] Cash Flow - The company's cash flow from operating activities for the year-to-date period was CNY 124,545,897.38, reflecting a significant increase of 68.66%[3] - The net cash flow from operating activities increased by 68.66% to CNY 124,545,897.38, up from CNY 73,843,578.16, driven by higher sales collections[8] - The net cash flow from operating activities for Q3 2021 was ¥124,545,897.38, up from ¥73,843,578.16 in Q3 2020, indicating a year-over-year increase of approximately 68.7%[33] - The net cash flow from investing activities was negative at -¥92,964,254.00 for Q3 2021, a decrease from a positive cash flow of ¥47,348,116.59 in Q3 2020[34] - The cash flow from investment activities decreased by 86.95% to CNY 55,404,902.45, down from CNY 424,568,895.95, due to reduced idle funds available for investment[8] Inventory and Receivables - The company's inventory increased by 34.10% to CNY 272,814,926.41, attributed to sales growth and preparations for Q4 sales[7] - The company's accounts receivable rose by 32.31% to CNY 230,409,831.10, driven by increased sales during the period[7] - Accounts receivable increased to ¥230,409,831.10, up 32.3% from ¥174,139,954.53[25] - Inventory rose to ¥272,814,926.41, an increase of 34.1% compared to ¥203,440,769.75[25] Expenses - Operating costs increased by 39.45% to CNY 645,126,454.28, up from CNY 462,605,565.31, primarily due to the significant rise in sales revenue[8] - Research and development expenses rose by 63.84% to CNY 35,245,649.30, compared to CNY 21,512,359.87, reflecting the company's commitment to new product development[8] - The company reported R&D expenses of ¥35,245,649.30, which is a 63.9% increase from ¥21,512,359.87 in the previous year[30] Shareholder Information - The company approved a share repurchase plan with a budget of between 20 million and 30 million RMB, with a maximum repurchase price of 7.45 RMB per share, and completed the repurchase of 4,215,800 shares by June 30, 2021[14] - The company plans to issue A-shares at a price of 4.63 RMB per share, raising between 100 million and 150 million RMB, with a minimum issuance of 21,367,522 shares[18] - As of October 12, 2021, the major shareholder Gaosen Investment reduced its holdings by 5,245,118 shares, bringing its total ownership to 4.99998%[23] - The company reported a total of 166,237,720 shares subject to lock-up at the end of the reporting period, with specific release schedules for executives[13] Future Plans - The company plans to continue expanding its market presence and investing in new technologies to support future growth[8] - The company has implemented new leasing standards starting from 2021, with no retrospective adjustments made[39]